CN119564619A - 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物 - Google Patents

治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物 Download PDF

Info

Publication number
CN119564619A
CN119564619A CN202411684617.XA CN202411684617A CN119564619A CN 119564619 A CN119564619 A CN 119564619A CN 202411684617 A CN202411684617 A CN 202411684617A CN 119564619 A CN119564619 A CN 119564619A
Authority
CN
China
Prior art keywords
subject
smoking
weeks
administration
vapor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411684617.XA
Other languages
English (en)
Chinese (zh)
Inventor
C·A·雅克布斯
D·F·蔡恩
A·科莱克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Archway Life Sciences
Original Assignee
Archway Life Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archway Life Sciences filed Critical Archway Life Sciences
Publication of CN119564619A publication Critical patent/CN119564619A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202411684617.XA 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物 Pending CN119564619A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962899637P 2019-09-12 2019-09-12
US62/899,637 2019-09-12
US202062988890P 2020-03-12 2020-03-12
US62/988,890 2020-03-12
CN202080064060.3A CN114727647A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
PCT/US2020/046308 WO2021050203A1 (en) 2019-09-12 2020-08-14 Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080064060.3A Division CN114727647A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物

Publications (1)

Publication Number Publication Date
CN119564619A true CN119564619A (zh) 2025-03-07

Family

ID=74866435

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202411684617.XA Pending CN119564619A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
CN202080064060.3A Pending CN114727647A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
CN202410180790.XA Pending CN118286217A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
CN202411683584.7A Pending CN119587493A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202080064060.3A Pending CN114727647A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
CN202410180790.XA Pending CN118286217A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
CN202411683584.7A Pending CN119587493A (zh) 2019-09-12 2020-08-14 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物

Country Status (11)

Country Link
US (3) US11083715B2 (https=)
EP (1) EP4027815B1 (https=)
JP (2) JP7742832B2 (https=)
KR (1) KR20220074895A (https=)
CN (4) CN119564619A (https=)
AU (1) AU2020346695A1 (https=)
BR (1) BR112022004519A2 (https=)
CA (1) CA3153405A1 (https=)
MX (1) MX2022002882A (https=)
WO (1) WO2021050203A1 (https=)
ZA (1) ZA202204075B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119564619A (zh) * 2019-09-12 2025-03-07 阿奇维生命科学公司 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
CA3230630A1 (en) * 2021-09-08 2023-03-16 Curtis SWIFT Analytical methods of assessing cytisine purity
JP2024095092A (ja) * 2022-12-28 2024-07-10 株式会社日立製作所 生成装置、生成方法、および生成プログラム
AU2024263979A1 (en) * 2023-04-26 2025-10-23 Achieve Life Sciences, Inc. Compositions comprising cytisine in the treatment and/or prevention of addiction in subjects in need thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983002892A1 (fr) 1982-02-22 1983-09-01 Talapin, Vitaly, Ivanovich Preparation medicinale possedant un effet antinicotine et son procede d'obtention
EP0937077B1 (en) * 1996-10-30 2006-05-17 Pfizer Inc. Pyridone-fused azabicyclic- or cytisine derivatives, their preparation and their use in addiction therapy
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
CN102014995B (zh) * 2007-03-30 2015-05-13 菲利普莫里斯生产公司 用于输送药剂的装置和方法
CN103284319A (zh) * 2013-06-20 2013-09-11 昌宁德康生物科技有限公司 一种金雀花碱替代尼古丁口腔雾化液及其制备方法
EP3011026B1 (en) * 2013-06-21 2019-12-18 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
US20160199315A1 (en) * 2013-08-23 2016-07-14 Hisamitsu Pharmaceutical Co., Inc. Adhesive patch
PL409829A1 (pl) * 2014-10-18 2016-04-25 Łukasz Zalewski Płyn z cytyzyną do elektronicznych papierosów
GB201602145D0 (en) * 2016-02-05 2016-03-23 Achieve Pharma Uk Ltd Salt
KR102848174B1 (ko) * 2017-07-24 2025-08-27 어치브 파마 유케이 리미티드 시티신 염
CN119564619A (zh) * 2019-09-12 2025-03-07 阿奇维生命科学公司 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物

Also Published As

Publication number Publication date
KR20220074895A (ko) 2022-06-03
EP4027815A4 (en) 2023-06-07
JP2022548876A (ja) 2022-11-22
CN118286217A (zh) 2024-07-05
JP2025081331A (ja) 2025-05-27
US20210077473A1 (en) 2021-03-18
CN119587493A (zh) 2025-03-11
US11083716B2 (en) 2021-08-10
BR112022004519A2 (pt) 2022-05-31
US20210077475A1 (en) 2021-03-18
EP4027815A1 (en) 2022-07-20
AU2020346695A1 (en) 2022-04-28
WO2021050203A1 (en) 2021-03-18
US20210330652A1 (en) 2021-10-28
JP7742832B2 (ja) 2025-09-22
MX2022002882A (es) 2022-05-10
EP4027815B1 (en) 2026-04-15
ZA202204075B (en) 2023-11-29
CN114727647A (zh) 2022-07-08
US11083715B2 (en) 2021-08-10
CA3153405A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
Henningfield et al. Pharmacotherapy for Nicotine Dependence 1
CN119564619A (zh) 治疗和/或预防有需要的受试者的成瘾的包括野靛碱的组合物
Newmeyer et al. Subjective and physiological effects, and expired carbon monoxide concentrations in frequent and occasional cannabis smokers following smoked, vaporized, and oral cannabis administration
Upadhyaya et al. Bupropion SR in adolescents with comorbid ADHD and nicotine dependence: a pilot study
Bailey et al. A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers
Anczak et al. Tobacco cessation in primary care: maximizing intervention strategies
WO2011020061A2 (en) Compositions and methods of for treating bipolar disorder
US20120225949A1 (en) Compositions and methods for treating bipolar disorder
Cornuz Smoking cessation interventions in clinical practice
Miller et al. Cigarette mentholation increases smokers' exhaled carbon monoxide levels.
Harlivasari et al. The role of twice-daily N-acetylcysteine (NAC) 2400 mg in smoking cessation: a randomized, placebo-controlled trial in Indonesia
CN121532188A (zh) 包含金雀花碱的组合物用于治疗和/或预防有此需要的受试者的成瘾
Klesges et al. Effects of phenylpropanolamine on withdrawal symptoms
Greydanus Substance abuse and adolescence
Farnam Zyban: a new aid to smoking cessation treatment--will it work for psychiatric patients?
Fagerström et al. Pharmacological treatments for tobacco dependence
US20200093764A1 (en) Treatment of asthma with cysteamine
Truong Stimulants and Co-occurring Substance Use
Glover Successfully treating nicotine dependence
Andrews et al. Nicotine addiction: Current treatment options
Clements Medications for Smoking Cessation
Pothula Safety and Efficacy of Alternative Tobacco Products in Smoking Cessation
JP2024514546A (ja) 亜酸化窒素により治療抵抗性うつ病性障害を治療するための組成物及び方法
CN121754541A (zh) 维生素b6在制备用于治疗过敏性鼻炎的药物中的应用
Hussain The impact of bupropion on cue-reactivity and the subjective effects of smoking in ad-lib smokers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination